The first regulatory approval of an allogeneic cell therapy goes to Atara Biotherapeutics. Other regulatory news highlights from the past week include proposed reforms of the FDA’s accelerated approval process, approval of the first gene therapy for bladder cancer, and a clinical hold for a biotech developing a new class of medicines.

The post Atara Approval Marks Cell Therapy First; Entrada on Hold, Bluebird Freed & More appeared first on MedCity News.

At the Alliance for Regenerative Medicine’s Cell & Gene Therapy Investor Day in New York Thursday, industry insiders gathered to talk about CAR-Ts in solid tumor cancers.

The post In CAR-Ts for solid tumors, is off-the-shelf the way to go? appeared first on MedCity News.

The company’s adoptive cell therapy produced responses in central nervous system PTLD, a frequently lethal complication of stem cell and solid organ transplants.

The post Atara’s EBV-CTLs show responses in hard-to-treat transplant complication appeared first on MedCity News.